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We evaluated the enhancing effect of structured treatment
interruptions (STIs) on HIV-specific immunity in chronically
HIV-1 infected Korean patients. A prospective case-control
study was done with a total of 10 subjects for a period of
26 weeks. Six subjects were on STIs and four subjects were
on continuous HAART for comparison. The STI subjects
underwent four periods of STIs. For those on STIs, HAART
was stopped at week 0 for two weeks, and resumed thereafter
for six weeks. Viral load and CD4+/CD8+ T cells were mea-
sured by HIV RNA RT-PCR and flow cytometry, and
HIV-specific immunity was measured by an ELISPOT assay.
HIV-specific cytotoxic T cell immunity was more pro-
nounced in the STI subjects than in the continuous HAART
subjects after 26 weeks (p = 0.011). The difference in cyto-
toxic T cell response in the STI group was more prominent
than in the continuous HAART group (p = 0.011). Viral load
after 26 weeks was higher in the STI subjects than in the
continuous HAART subjects (p = 0.008). An HIV-specific
cellular immune response can be stimulated by STIs in
chronically HIV-infected Koreans. A larger study is war-
ranted in order to further characterize viral and immunolo-
gical parameters of treatment with STIs in cases of chronic
HIV infection.
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Highly active antiretroviral therapy (HAART) is
associated with both virological and immunologi-
cal benefits in human immunodeficiency virus
(HIV) infection and acquired immunodeficiency
syndrome (AIDS). HAART has also been known
to reduce AIDS-related mortality.1 Despite these
benefits, when used alone HAART has proven
insufficient to completely eliminate viral reser-
voirs, even after decades of treatment.2 Structured
treatment interruptions (STIs) have been inves-
tigated as a means of improving viral control via
the augmentation of HIV-1-specific cellular im-
mune responses, with the additional potential
benefits of reduced drug exposure and lower
costs.
Results have thus far been encouraging for
patients who undergo STIs following HAART
when initiated during the period of acute
infection.3,4 However, the benefits of STIs in those
chronically infected is less clear. Studies indicate
that only a minority of chronically infected indi-
viduals are able to maintain viral suppression
after STIs without HAART, although most
patients exhibit increased antiviral cellular im-
mune responses.5 Furthermore, rapid declines in
peripheral CD4+ T-cell counts have been observed
during STIs.6,7 These CD4+ T-cell declines are
inversely proportional to increases in plasma
HIV-1 RNA levels during STIs, and are generally
followed by a return to pre-interruption CD4+
T-cell levels after the re-initiation of HAART.
7
To date, there has been no study conducted
regarding the effects of STIs in HIV infected
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Koreans. Therefore, in this report we have eval-
uated the effect of STIs with respect to the
augmentation of HIV-specific immunity and con-
trolling viral replication in chronically HIV-1 in-
fected Korean patients.
A prospective case-control study was per-
formed with a total of 10 patients. Six were on
STIs and four were on continuous HAART for
comparison purposes. Study subjects were en-
rolled in the study if they met the following
criteria: chronically HIV-1 infected Koreans
between the ages of 18 and 50 years old; having
a viral load (RT-PCR) in plasma < 25 copies/mL
for 12 months after HAART; and CD4+ cell counts
300 cells/ l. Informed consent was obtainedμ
from all subjects.
The STI subjects underwent four periods of
STI. For those subjects on STIs, HAART was
stopped at week 0 of the study for two weeks,
and was resumed thereafter for six weeks (week
2 to week 8). This cycle was repeated four times.
Antiretroviral therapy for all study subjects con-
sisted of a protease inhibitor and two nucleoside
reverse-transcriptase inhibitors (standard doses of
lamivudine and zidovudine). The protease in-
hibitors were indinavir or nelfinavir. After each
interruption, medical visits were scheduled at
day 0 and were continued weekly thereafter.
Viral load and CD4+/CD8+ T cell levels were
assessed via a HIV RNA RT-PCR and flow
cytometry. HIV-specific cellular immunity was
measured by an interferon- ELISPOT assay. Theγ
interferon- ELISPOT assay, as described preγ -
viously, was performed on frozen PBMCs (peri-
pheral blood mononuclear cells) from all 10
subjects.8,9 Cells in triplicate were stimulated by
pools of 9-11 synthetic 15-mer peptides over-
lapping by 11 amino acids, which spanned the
entire HIV-1 gag sequence (each peptide, 2 g/μ
mL). Negative and positive controls were admi-
nistered medium alone and phytohemagglutinin
(1 g/mL), respectively. Results are expressed asμ
the number of spot-forming cells (SFC) per 106
PBMCs. The number of HIV-1 specific interferon-
producing CD8+ T-cells was calculated by subγ -
tracting the number of spot-forming cells in the
Table 1. Baseline Characteristics and Immunological and Virological Parameters in the Structured Treatment Interruption
(STI) and Continuous Highly Active Antiretroviral Therapy (HAART) Subjects
Demographic/Immunological/Virological
parameters
STI (n = 6) HAART (n = 4) p value
Age (yrs) 45 (35 - 47) 43 (41 - 45) NS
Sex (male:female) 5:1 3:1
Protease inhibitors received, no. of patients NS
Indinavir 4 2
Nelfinavir 2 2
Initial CD4+ T cells (/ L)μ 698.0 (446.7 - 893.5) 728.0 (713.5 - 786.7) NS
Final CD4+ T cells (/ L)μ 652.5 (456.5 - 830.0) 788.5 (741.5 - 825.7) NS
Initial CD8+ T cells (/ L)μ 590.5 (441.2 - 985.7) 789.5 (646.5 - 967.0) NS
Final CD8+ T cells (/ L)μ 1139.0 (672.5 - 1355.7) 780.0 (641.2 - 972.0) NS
Initial plasma HIV RNA (copies/mL) < 25 < 25 NS
Final plasma HIV RNA (copies/mL) 6,386.0 (118.0 - 20,325.0) < 25 0.008
Initial CTL responses (SFCs/106 PBMCs) 108.0 (34.7 - 147.7) 107.5 (45.0 - 140.0) NS
Final CTL responses (SFCs/106 PBMCs) 515.5 (243.0 - 741.5) 112.5 (66.7 - 141.0) 0.011
Changes of CTL response (SFCs/106 PBMCs) 406.0 (214.7 - 596.0) 11.0 (4.5 - 27.2) 0.011
NS, not significant.
Data are shown as ‘median value (interquartile range)’.
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negative control from the peptide-stimulated
cells.
We then compared the HIV-specific immunity
response, immunological parameters, and virolo-
gical parameters between the STI and the con-
tinuous HAART subjects. Continuous variables
were compared using the Mann-Whitney U test.
A p-value < 0.05 was considered to be statistically
significant. The SPSS (version 11.0) software pack-
age was used for all analyses. Data were expressed
as the ‘median value (interquartile range)’.
There were no statistically significant differ-
ences between the STI subjects and the continuous
HAART subjects with respect to age, sex, or dura-
tion of known HIV-1 infection. No patient had
conditions defining AIDS during the study.
Table 1 displays the immunological and virolo-
gical parameters in both the STI subjects and the
continuous HAART subjects. Final CD4+ T cell
counts were lower in STI subjects than in the
continuous HAART subjects, but this difference
was not significantly different (652.5 (456.5-830.0)
/ L vs. 788.5 (741.5-825.7)/ L). Plasma HIV RNAμ μ
levels after 26 weeks were higher in the STI sub-
jects than in the continuous HAART subjects
(6,386.0 (118.0-20,325.0) copies/mL vs. < 25 copies/
mL, p = 0.008). HIV-specific cytotoxic T cell im-
munity after 26 weeks, as measured by the
Fig. 1. Changes of immunological and virological parameters after treatment interruption schedules in the STI group. ( ,
CD4 cell counts (/ L); , CD8 cell counts (/ L); , Cytotoxic T lymphocyte responses (SFC/10μ μ 6 PBMC); , Viral load
(copies/mL))
patient 1 patient 2
patient 3 patient 4
patient 5 patient 6
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ELISPOT assay, was more pronounced in the STI
subjects than in the continuous HAART subjects
(515.5 (243.0-741.5) SFCs/106 PBMC vs. 112.5 (66.7-
141.0) SFCs/106 PBMC, p = 0.011). The changes of
CTL (cytotoxic T lymphocyte) response in the STI
group were more prominent than in the con-
tinuous HAART group (406.0 (214.7-596.0) SFCs/
106 PBMC vs. 11.0 (4.5-27.2) SFCs/106 PBMC, p =
0.011).
Fig. 1 shows the changes of immunological and
virological parameters after each scheduled STI.
After STIs, cytotoxic T lymphocyte (CTL) res-
ponses were stimulated, CD8 + T cell counts in-
creased, and the viral load gradually increased in
most patients.
It has been hypothesized that cyclical inter-
ruptions of antiretroviral therapy may boost HIV-
1-specific immune responses, reset viral loads,
and might constitute a novel modality of immune-
based therapy in cases of HIV-1 infection, but only
when initiated at the period of acute infection.3
However, these immune-specific responses seem
to be weaker when STIs were performed during
a chronic HIV infection. Moreover, there is con-
tradictory evidence regarding the possibility of an
association between these immune responses and
the reset of the viral load set-point, which occurs
in a low proportion of patients (approximately
20% of patients with chronic HIV infection).5
This study demonstrates that HIV-1 specific
cellular immune responses were augmented fol-
lowing cycles of STIs in chronically HIV-1 infected
Koreans. Chronically HIV-infected Korean in-
dividuals exhibited similar immunological re-
sponses to STIs as reported in other studies,
which suggests that race may not be involved in
the factors influencing an STI response.3-5,7
Recently, a prospective, randomized trial of STIs
for chronically HIV-1 infected Thai patients was
reported.10 This STI trial demonstrated that
adequate immunological function could be pre-
served by the use of a CD4 cell count-guided
method or a week-on/week-off approach to
therapy withdrawal and reintroduction, compared
with the continuous antiretroviral therapy in Thai
patients. The study found that the week-on/
week-off therapy was associated with a higher
virological failure rate.
There are several important safety issues in-
herent in the STI protocols.11 One concern is the
potential development of drug resistance. We did
not assess drug resistance by genotyping, and so
are unaware of any mutations known to be asso-
ciated with resistance to reverse transcriptase or
protease inhibitors in the study population.
Another concern was the possibility that viremia
would not be re-suppressed upon the re-initiation
of therapy. Viral loads dropped below 25 copies/
mL in all patients within one month of re-intro-
duction of the same antiretroviral regimen. These
findings are consistent with the observations in
other previous studies on antiretroviral therapy
interruption.12 Another safety concern associated
with the STI protocols tested in this study was the
potential drop in total CD4 T-cell counts after the
viral load rebound. In another study, the CD4+
T-cell count decline was inversely proportional to
increases in plasma HIV-1 RNA levels during
STIs, and were generally followed by a return to
pre-interruption CD4+ T-cell levels after the
reinstatement of HAART.7 In our study, final
CD4+ T cell counts were lower in STI subjects
than in continuous HAART subjects, but this
difference was not significant.
Chronically HIV-1 infected subjects are charac-
terized by a significantly higher degree of immu-
nosuppression than primary HIV-1 infected sub-
jects, and they also tend to harbor more diverse
viral sequences, requiring broader immune re-
sponses for viral control.13,14 Therefore, strategies
designed to stimulate broader immunity and
potentiate sufficient helper T cell functions are
necessary for immune-based therapies, such as
STIs, in terms of controlling viral replication in
these chronically HIV-infected patients.
Our study has some limitations, the most im-
portant of which is the small number of patients
enrolled. In addition, we interrupted HAART
according to the duration of HAART, but took
neither CD4+ T cell counts nor the viral load into
consideration.
In conclusion, HIV-specific cellular immune
response can be stimulated by STIs in chronically
HIV-infected Koreans. A larger study is warranted
in order to further characterize viral and im-
munological parameters after STIs in cases of
chronic HIV infection.
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